Wed, May 11, 2022

Keay Nakae Maintained (ARWR) at Strong Buy with Decreased Target to $80 on, May 11th, 2022

Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Decreased Target from $94 to $80 on, May 11th, 2022.

Keay has made no other calls on ARWR in the last 4 months.



There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, 0 agree with Keay's Rating of Hold.



This is the rating of the analyst that currently disagrees with Keay


  • Madhu Kumar of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Wednesday, January 19th, 2022